Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting

Halperin, Abigail; McAfee, Tim; Jack, Lisa M.; Catz, Sheryl L.; McClure, Jennifer B.; Deprey, T. Mona; Richards, Julie; Zbikowski, Susan M.; Swan, Gary E.

doi:10.1016/j.jsat.2008.09.001

Cited by 48 publications

(41 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concerns have been raised about the incidence and severity of adverse events, particularly with regard to bupropion and varenicline (Barrueco et al, 2005;Halperin et al, 2009). Nonetheless, early discontinuation (within the first week) attributed to side effects or to a legitimate medical reason was uncommon, reported by only 4% of the sample overall.…”

Section: Discussionmentioning

confidence: 99%

“…In part because they require a doctor consultation, these medications have really only been tested in the presence of structured support. For both, adverse events leading to discontinuation are commonly reported (Barrueco et al, 2005;Halperin et al, 2009), although side effects are typically mild (Cahill et al, 2008;Zwar & Richmond, 2003). In Australia and the United Kingdom, a second prescription is needed to receive the full course of treatment of both bupropion and varenicline, which may act as a barrier to adherence.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adherence to and Reasons for Premature Discontinuation From Stop-Smoking Medications: Data From the ITC Four-Country Survey

Balmford

Borland

Hammond

et al. 2010

Nicotine & Tobacco Research

136

151

View full text Add to dashboard Cite

Introduction: Nicotine replacement therapies (NRTs) have been demonstrated to be effective in clinical trials but may have lower efficacy when purchased over-the-counter (OTC). Premature discontinuation and insufficient dosing have been offered as possible explanations. The aims are to (a) investigate the prevalence of and reasons for premature discontinuation of stop-smoking medications (including prescription only) and (b) how these differ by type, duration of use, and source (prescription or OTC). Methods:The sample includes 1,219 smokers or recent quitters who had used medication in the last year (80.5% NRT, 19.5% prescription only). Data were from Waves 5 and 6 of the International Tobacco Control (ITC) Four-Country Survey.Results: Most of the sample (69.1%) discontinued medication use prematurely. This was more common among NRT users (71.4%) than in users of bupropion and varenicline (59.6%). OTC NRT users were particularly likely to discontinue (76.3%). Relapse back to smoking was the most common reason for discontinuation of medication reported by 41.6% of respondents. Side effects (18.3%) and believing that the medication was no longer needed (17.1%) were also commonly reported. Of those who completed treatment, 37.9% achieved 6-month continuous abstinence compared with 15.6% who discontinued prematurely. Notably, 65.6% who discontinued because they believed the medication had worked were abstinent. Conclusions:Premature discontinuation of stop-smoking medications is common but is not a plausible reason for poorer quit outcomes for most people. Encouraging persistence of medication use after relapse or in the face of minor side effects may help increase long-term cessation outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adherence to and Reasons for Premature Discontinuation From Stop-Smoking Medications: Data From the ITC Four-Country Survey

Balmford

Borland

Hammond

et al. 2010

Nicotine & Tobacco Research

136

151

View full text Add to dashboard Cite

show abstract

“…Telephone follow-up surveys were conducted by nonintervention study staff approximately 21 days, 12 weeks, and 6 months after the target quit date to collect information on quit attempts, smoking, and medication adherence. At 21 days and 12 weeks, participants were also asked if during the past month, they experienced any of a number of treatment-related symptoms including known medication side effects (e.g., nausea, vomiting, change in appetite) and nicotine abstinence effects (e.g., irritability, desire to smoke; Halperin et al, 2009;McClure et al, 2009). Severity of symptoms and side effects endorsed in the past month was rated by participants on a Likert scale from 1 (very mild) to 5 (very severe), with 0 on this scale signifying "not present.…”

Section: Methodsmentioning

confidence: 99%

Adherence to Varenicline in the COMPASS Smoking Cessation Intervention Trial

Catz

Jack

McClure

et al. 2011

Nicotine & Tobacco Research

102

View full text Add to dashboard Cite

“…Detailed study methods and results are presented elsewhere (Halperin et al, 2008;McClure et al, 2009;Swan et al, 2010). Briefly, the COMPASS study was a randomized trial comparing the effectiveness of three forms of behavioral intervention for smoking cessation (delivered by Web, phone, or an integrated phone-Web program) in conjunction with varenicline.…”

Section: Methodsmentioning

confidence: 99%

Utilization of Services in a Randomized Trial Testing Phone- and Web-Based Interventions for Smoking Cessation

Zbikowski¹,

Jack

McClure

et al. 2011

Nicotine & Tobacco Research

View full text Add to dashboard Cite

Introduction: Phone counseling has become standard for behavioral smoking cessation treatment. Newer options include Web and integrated phone-Web treatment. No prior research, to our knowledge, has systematically compared the effectiveness of these three treatment modalities in a randomized trial. Understanding how utilization varies by mode, the impact of utilization on outcomes, and predictors of utilization across each mode could lead to improved treatments. Methods:One thousand two hundred and two participants were randomized to phone, Web, or combined phone-Web cessation treatment. Services varied by modality and were tracked using automated systems. All participants received 12 weeks of varenicline, printed guides, an orientation call, and access to a phone supportline. Self-report data were collected at baseline and 6-month follow-up.Results: Overall, participants utilized phone services more often than the Web-based services. Among treatment groups with Web access, a significant proportion logged in only once (37% phone-Web, 41% Web), and those in the phone-Web group logged in less often than those in the Web group (mean = 2.4 vs. 3.7, p = .0001). Use of the phone also was correlated with increased use of the Web. In multivariate analyses, greater use of the phone-or Web-based services was associated with higher cessation rates. Finally, older age and the belief that certain treatments could improve success were consistent predictors of greater utilization across groups. Other predictors varied by treatment group. Conclusions:Opportunities for enhancing treatment utilization exist, particularly for Web-based programs. Increasing utilization more broadly could result in better overall treatment effectiveness for all intervention modalities.

show abstract

Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting

Cited by 48 publications

References 12 publications

Adherence to and Reasons for Premature Discontinuation From Stop-Smoking Medications: Data From the ITC Four-Country Survey

Adherence to and Reasons for Premature Discontinuation From Stop-Smoking Medications: Data From the ITC Four-Country Survey

Adherence to Varenicline in the COMPASS Smoking Cessation Intervention Trial

Utilization of Services in a Randomized Trial Testing Phone- and Web-Based Interventions for Smoking Cessation

Contact Info

Product

Resources

About